Public Release: 

Biomarkers predict time to ovarian cancer recurrence

JCI Journals

Ovarian cancer often remains undetected until it is at an advanced stage. Despite positive responses to initial treatment, many patients are at risk of tumor recurrence. A multitude of genetic markers have been implicated in ovarian cancer prognosis. However, the genetic testing required is not practical or affordable in a clinical setting.

In this issue of the Journal of Clinical Investigation, Roel Verchaak and colleagues at the MD Anderson Cancer Center identify protein biomarkers that are predictive for time of ovarian cancer recurrence and develop a PRotein-driven index of OVARian cancer (PROVAR).

Using PROVAR, the authors were able to discriminate between patients with high and low risk of cancer recurrence, as well as short-term and long-term survival prognosis. In combination with genetic diagnosis, analysis of protein biomarkers may be useful in predicting outcome and determining a treatment plan for ovarian cancer patients.

###

TITLE: Predicting Time to Ovarian Carcinoma Recurrence Using Protein Markers

AUTHOR CONTACT: Roel G.W. Verhaak
MD Anderson Cancer Center, Houston, TX, USA
Phone: 7135632293; E-mail: RVerhaak@mdanderson.org

View this article at: http://www.jci.org/articles/view/68509?key=d03afe0843e018bcf8a0

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.